In vitro synergy of paclitaxel (Taxol) and vinorelbine (Navelbine) against human melanoma cell lines

European Journal of Cancer Part A

Volumn 33, Issue 3, 1997, Pages 463-470

  Photiou, A ^a   Shah, P ^a   Leong, L K ^a   Moss, J ^b   Retsas, S ^a  

^a Melanoma Unit   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

annulate lamellae; drug combinations; isobolograms; melanoma; paclitaxel; tubulin immunofluorescence; vinorelbine

Indexed keywords

NAVELBINE; PACLITAXEL; TUBULIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL;

EID: 0031106360     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)89023-5     Document Type: Article

References (49)

1. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 277:1979;665-667.
2. Slichenmeyer WJ, Von Hoff DD. New natural products in cancer chemotherapy. J Clin Pharmacol. 9:1990;770-788.
3. Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys. 22:1992;613-617.
4. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from Taxol. J Clin Oncol. 8:1990;1263-1268.
5. Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A phase II trial of Taxol in metastatic melanoma. Cancer. 65:1990;2478-2481.
6. Einzig AI, Hochster H, Wiernik PH, et al. A phase II study of Taxol in patients with malignant melanoma. Invest New Drugs. 9:1991;59-64.
7. Wiernik PH, Einzig AI. Taxol in malignant melanoma. Monogr Natl Cancer Inst. 15:1993;185-187.
8. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet. 344:1994;1267-1272.
9. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res. 48:1988;4093-4100.
10. Manfredi JJ, Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmac Ther. 25:1984;83-125.
11. Jordan MA, Thrower D, Wilson L. Effects of vinblastine podophyllotoxin and nocodazole on the mitotic spindles: implications for the role of microtubule dynamics in mitosis. J Cell Sci. 102:1992;401-416.
12. Toso RJ, Jordan MA, Farrell W, Matsumoto B, Wilson L. Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine. Biochemistry. 32:1993;1285-1293.
13. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol. 91:1981;479-487.
14. Fellous A, Ohayon R, Vacassin T, et al. Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol. 16:(Suppl 4):1989;9-14.
15. Retsas S, Peat I, Ashford R, et al. Updated results of vindesine as a single agent in the therapy of advanced malignant melanoma. Cancer Treat Rev. 7:1980;87-90. (Suppl).
16. Carmichael J, Atkinson RJ, Calman KC, Mackie RM, Naysmith AM, Smyth JF. A multicentre phase II trial of vindesine in malignant melanoma. Eur J Cancer Clin Oncol. 18:1982;1293-1295.
17. Quagliana JM, Stephens RL, Baker LH, Costanzi JJ. Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study. J Clin Oncol. 2:1984;316-319.
18. Retsas S, Quigley M, Pectasides D, Macrae K, Henry K. Clinical and histologic involvement of regional lymph nodes in malignant melanoma: adjuvant vindesine improves survival. Cancer. 73:1994;2119-2130.
19. Retsas S, Bayliss M, Sheikh N, Chong SL, et al. Chemotherapy of malignant melanoma: the European Experience. Rev Med Interne. 11:(Suppl 2):1990;51-58.
20. Retsas S. Strategies for improving survival in malignant melanoma: focus on vindesine. J Drug Devel Clin Practice. 7:1995;159-171.
21. Pinedo HM, Van-Groeningen CJ. Vinorelbine: a horse of a different color? [Editorial] J Clin Oncol. 12:1994;1745-1747.
22. Langlois N, Gueritte F, Langlois Y, Potier P. Application of a modification of the Polonovski reaction to the synthesis of vinblastine-type alkaloids. J Am Chem Soc. 98:1976;7017-7024.
23. Photiou A, Sheikh MN, Bafaloukos D, Retsas S. Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines. J Cancer Res Clin Oncol. 118:1992;249-254.
24. Casey SJ, Quigley M, Retsas S. Phase II study of vinorelbine (VRB) in metastatic malignant melanoma (MMM). Eur J Cancer. (Suppl 2):1991;954. (abstract).
25. Tolis C, Photiou A, Camplejohn RS, Retsas S. Growth inhibitory activity of S12363, a novel vinca alkaloid derivative on human melanoma cell lines. Anticancer Res. 13:1993;161-166.
26. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 82:1990;1107-1112.
27. Houghton PJ, Photiou A, Uddin S, et al. Activity of extracts of Kigelia pinnata against melanoma and renal carcinoma cell lines. Planta Medica. 60:1994;430-433.
28. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 5:1979;85-91.
29. Okano T, Ohnuma T, Holland JF, Koeffler HP, Jui H. Effects of harringtonine in combination with activicin, adriamycin, L-asparaginase, cytosine arabinoside, dexamethasone, fluorouracil or methotrexate on human acute myelogenous leukemia cell line KG-1. Invest New Drugs. 1:1983;145-150.
30. Nocentini G, Barzi A, Franchetti P. Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase. Cancer Chemother Pharmacol. 26:1990;345-351.
31. Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzymol Regul. 22:1984;27-55.
32. Chou J, Chou T-C, Dose-Effect Analysis with Microcomputers. Cambridge, U.K. Biosoft Ltd.
33. Chou T-C, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci. 4:1983;450-454.
34. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 51:1991;2212-2222.
35. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA. 90:1993;9552-9556.
36. Wilson L, Toso RJ, Jordan MA. Vinblastine, nocodazole and colchicine suppress the dynamic instability of microtubules: implications for the mechanism of antimitotic action. Cellular Pharmacol. 1:(Suppl 1):1993;S35-S40.
37. Wendell KL, Wilson L, Jordan MA. Mitotic block in HeLa cells by vinblastine: ultrastructural changes in kinetochoremicrotubule attachment and in centrosomes. J Cell Sci. 104:1993;261-274.
38. 1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telphase. Cancer Res. 54:1994;4355-4361.
39. Longnecker SM, Donehower RC, Cates RC, et al. High performance liquid chromatographic assay for taxol (NSC 125973) in human plasma and urine pharmacokinetics in a phase I trial. Cancer Treat Rep. 71:1986;53-59.
40. Rahmani RM, Bruno R, Iliadis A, et al. Clinical pharmacokinetics of the antitumour drug Navelbine (5′-noranhydrovinblastine). Cancer Res. 47:1987;5796-5799.
41. Kessel RG. The annulate lamellae; from obscurity to spotlight. Electron Microsc Rev. 2:1989;257.
42. Wang NS, Lin C, Emond J, Tsao MS. Annulate lamellae in a large cell lung carcinoma cell line with high expression of tyrosine kinase receptor and protooncogenes. Ultrastruct Pathol. 16:1992;439-449.
43. Nakayama I, Moriuchi A, Taira Y, Takahara O, Itoga T, Tsuda N. Fine structural study of annulate lamellae complexes in human tumors. Acta Pathol Jpn. 27:1977;25-39.
44. Tschang TP, Kasin JV, Parnell D, Kraus FT. Annulate lamellae in human malignant tumors. Report of three cases. Arch Pathol Lab Med. 102:1978;426-430.
45. Kantzky M, Schenk P. Schwannom der Nase und der Nasennebenhohlen. Laryngorhinootologie. 68:1989;547-551.
46. Krishan A, Hsu D, Hutchins P. Hypertrophy of granular endoplasmic reticulum and annulate lamellae in Earle's L cells exposed to vinblastine sulphate. J Cell Biol. 39:1968;211-216.
47. Chemnitz J, Salmberg K, Bierring F. Observations on the association of annulate lamellae in vinblastine-induced paracrystals in tumour cells in vitro. Virchows Arch B Cell Pathol. 24:1977;147-156.
48. Kessel RG, Katow H. Effects of prolonged antitubulin culture on annulate lamellae in mouse alpha L929 fibroblasts. J Morphol. 179:1984;291-304.
49. Retsas S, Mohith A, Mackenzie H. Taxol and vinorelbine: a new active combination for disseminated malignant melanoma. Anticancer Drugs. 7:1996;1-5.